Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT ID: NCT00228969
Last Updated: 2012-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2005-02-28
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RWJ-333369
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of epilepsy for at least 1 year,
3. Presenting, on average, at least 3 partial onset seizures per month,
4. Currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 anti-epileptic drugs (AEDs),
Exclusion Criteria
2. Have any serious diseases,
3. History of major psychiatric disorders within the past 2 years.
4. Have received an experimental drug/device within the past 30 days
5. Are pregnant or breastfeeding.
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Life Science, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Northport, Alabama, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Irvine, California, United States
Northridge, California, United States
Sacramento, California, United States
Fort Collins, Colorado, United States
Wilmington, Delaware, United States
Decatur, Georgia, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Baton Rouge, Louisiana, United States
Golden Valley, Minnesota, United States
Saint Paul, Minnesota, United States
Chesterfield, Missouri, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Sellersville, Pennsylvania, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
El Paso, Texas, United States
Bennington, Vermont, United States
Charlottesville, Virginia, United States
Roanoke, Virginia, United States
Madison, Wisconsin, United States
Ciudad de Buenos Aires, , Argentina
Córdoba, , Argentina
Salta, , Argentina
Budapest, , Hungary
Debrecen, , Hungary
Győr, , Hungary
Pécs, , Hungary
Zalaegerszeg-Pozva, , Hungary
Breda, , Netherlands
Heemstede, , Netherlands
Heeze, , Netherlands
Rotterdam, , Netherlands
Gdansk, , Poland
Katowice, , Poland
Kielce, , Poland
Krakow, , Poland
Lublin, , Poland
Mosina, , Poland
Warsaw, , Poland
Zabrze, , Poland
Moscow, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Barcelona, , Spain
Madrid, , Spain
Málaga, , Spain
Pamplona, , Spain
Glasgow, , United Kingdom
Middlesbrough, , United Kingdom
Northampton, , United Kingdom
Oxford, , United Kingdom
Reading, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lu C, Zheng J, Cao Y, Bresnahan R, Martin-McGill KJ. Carisbamate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD012121. doi: 10.1002/14651858.CD012121.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
333369-EPY-2003
Identifier Type: -
Identifier Source: org_study_id